Citius Pharmaceuticals (NASDAQ:CTXR) Stock Rating Upgraded by D. Boral Capital

D. Boral Capital upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a buy rating in a report released on Monday morning, Marketbeat.com reports. D. Boral Capital currently has $9.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Trading Up 6.3 %

Shares of CTXR opened at $3.91 on Monday. The firm’s 50-day moving average is $5.63 and its two-hundred day moving average is $12.03. Citius Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $26.75. The firm has a market capitalization of $28.27 million, a P/E ratio of -0.65 and a beta of 1.48.

Institutional Trading of Citius Pharmaceuticals

Several large investors have recently modified their holdings of the business. Point72 DIFC Ltd purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at approximately $29,000. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the third quarter valued at $47,000. Miller Investment Management LP boosted its stake in shares of Citius Pharmaceuticals by 99.3% during the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after acquiring an additional 49,640 shares during the last quarter. Virtu Financial LLC purchased a new stake in Citius Pharmaceuticals during the 3rd quarter worth about $50,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $69,000. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.